α1-A680T variant in GUCY1A3 as a candidate conferring protection from pulmonary hypertension among kyrgyz highlanders

Circulation: Cardiovascular Genetics

Volumn 7, Issue 6, 2014, Pages 920-929

  Wilkins, Martin R ^a   Aldashev, Almaz A ^b   Wharton, John ^a   Rhodes, Christopher J ^a   Vandrovcova, Jana ^c   Kasperaviciute, Dalia ^d   Bhosle, Shriram G ^d   Mueller, Michael ^d   Geschka, Sandra ^e   Rison, Stuart ^a   Kojonazarov, Baktybek ^g   Morrell, Nicholas W ^h   Neidhardt, Inga ⁱ   Surmeli, Nur Basak ^j   Aitman, Tim J ^c   Stasch, Johannes Peter ^e,f   Behrends, Soenke ⁱ   Marletta, Michael A ^j  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b Kyrgyz National Academy of Sciences   (Kyrgyzstan)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e BAYER PHARMA AG   (Germany)

^f MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^g JUSTUS LIEBIG UNIVERSITY   (Germany)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^j SCRIPPS RESEARCH INSTITUTE   (United States)

more..

Author keywords

Cyclic nucleotide; Exome; Hypoxia; Pulmonary hypertension

Indexed keywords

CYCLIC GMP; GUANYLATE CYCLASE; NITRIC OXIDE; CELL RECEPTOR; SOLUBLE GUANYLYL CYCLASE;

ADULT; AGED; ALTITUDE; ARTICLE; BLOOD VESSEL REACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; EXOME; FEMALE; FRAMESHIFT MUTATION; GENE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; GUCY1A3 GENE; HUMAN; HUMAN CELL; HYPOXIA; IN VITRO STUDY; KYRGYZ (PEOPLE); LUNG ARTERY PRESSURE; MALE; MISSENSE MUTATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; ALLELE; ALTITUDE DISEASE; AMINO ACID SEQUENCE; ANIMAL; DNA SEQUENCE; GENETICS; GENOTYPE; HEK293 CELL LINE; HIGH THROUGHPUT SEQUENCING; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; PATHOLOGY; PHYLOGENY; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ALLELES; ALTITUDE SICKNESS; AMINO ACID SEQUENCE; ANIMALS; CYCLIC GMP; FEMALE; GENOTYPE; GUANYLATE CYCLASE; HEK293 CELLS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NITRIC OXIDE; PHYLOGENY; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SEQUENCE ALIGNMENT; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION;

EID: 84925846230     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.114.000763     Document Type: Article

References (42)

1. Sylvester JT, Shimoda LA, Aaronson PI, Ward JP. Hypoxic pulmonary vasoconstriction. Physiol Rev. 2012;92:367-520. doi: 10.1152/ physrev.00041.2010
2. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res. 2006;99:675-691. doi: 10.1161/01.RES.0000243584.45145.3f
3. Aldenderfer M. Peopling the Tibetan plateau: insights from archaeology. High Alt Med Biol. 2011;12:141-147. doi: 10.1089/ham.2010.1094
4. Groves BM, Droma T, Sutton JR, McCullough RG, McCullough RE, Zhuang J, et al. Minimal hypoxic pulmonary hypertension in normal Tibetans at 3,658 m. J Appl Physiol (1985). 1993;74:312-318
5. Aldashev AA, Sarybaev AS, Sydykov AS, Kalmyrzaev BB, Kim EV, Mamanova LB, et al. Characterization of high-altitude pulmonary hypertension in the Kyrgyz: association with angiotensin-converting enzyme genotype. Am J Respir Crit Care Med. 2002;166:1396-1402. doi: 10.1164/rccm.200204-345OC
6. Winger JA, Derbyshire ER, Marletta MA. Dissociation of nitric oxide from soluble guanylate cyclase and heme-nitric oxide/oxygen binding domain constructs. J Biol Chem. 2007;282:897-907. doi: 10.1074/jbc. M606327200
7. O'Callaghan DS, Savale L, Montani D, Jaïs X, Sitbon O, Simonneau G, et al. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol. 2011;8:526-538. doi: 10.1038/nrcardio.2011.104
8. Simonson TS, Yang Y, Huff CD, Yun H, Qin G, Witherspoon DJ, et al. Genetic evidence for high-altitude adaptation in Tibet. Science. 2010;329:72-doi: 10.1126/science.1189406
9. Schmidt PM, Schramm M, Schröder H, Wunder F, Stasch JP. Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J Biol Chem. 2004;279:3025-3032. doi: 10.1074/jbc.M310141200
10. Schmidt PM, Rothkegel C, Wunder F, Schröder H, Stasch JP. Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase. Eur J Pharmacol. 2005;513:67-74. doi: 10.1016/j.ejphar.2005.02.046
11. Rothkegel C, Schmidt PM, Stoll F, Schröder H, Schmidt HH, Stasch JP. Identification of residues crucially involved in soluble guanylate cyclase activation. FEBS Lett. 2006;580:4205-4213. doi: 10.1016/j. febslet.2006.06.079
12. Rothkegel C, Schmidt PM, Atkins DJ, Hoffmann LS, Schmidt HH, Schröder H, et al. Dimerization region of soluble guanylate cyclase characterized by bimolecular fluorescence complementation in vivo. Mol Pharmacol. 2007;72:1181-1190. doi: 10.1124/mol.107.036368
13. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001;410:212-215. doi: 10.1038/35065611
14. Stasch J-P, Evgenov OV. Pharmacotherapy of Pulmonary Hypertension. Berlin, Heidelberg: Springer; 2013
15. Busker M, Neidhardt I, Behrends S. Nitric oxide activation of guanylate cyclase pushes the 1 signaling helix and the 1 heme-binding domain closer to the substrate-binding site. J Biol Chem. 2014;289:476-484. doi: 10.1074/jbc.M113.504472
16. Follmann M, Griebenow N, Hahn MG, Hartung I, Mais FJ, Mittendorf J, et al. The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew Chem Int Ed Engl. 2013;52:9442-9462. doi: 10.1002/anie.201302588
17. Fagan KA, McMurtry I, Rodman DM. Nitric oxide synthase in pulmonary hypertension: lessons from knockout mice. Physiol Res. 2000;49: 539-548
18. Zhao L, Crawley DE, Hughes JM, Evans TW, Winter RJ. Endotheliumderived relaxing factor activity in rat lung during hypoxic pulmonary vascular remodeling. J Appl Physiol (1985). 1993;74:1061-1065
19. Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation. 2004;109:3106-3111. doi: 10.1161/01.CIR.0000134595.80170.62
20. Ghofrani HA, Reichenberger F, Kohstall MG, Mrosek EH, Seeger T, Olschewski H, et al. Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. Ann Intern Med. 2004;141:169-177
21. Aldashev AA, Kojonazarov BK, Amatov TA, Sooronbaev TM, Mirrakhimov MM, Morrell NW, et al. Phosphodiesterase type 5 and high altitude pulmonary hypertension. Thorax. 2005;60:683-687. doi: 10.1136/thx.2005.041954
22. Li D, Zhou N, Johns RA. Soluble guanylate cyclase gene expression and localization in rat lung after exposure to hypoxia. Am J Physiol. 1999;277[4 pt 1]:L841-L847
23. Dumitrascu R, Weissmann N, Ghofrani HA, Dony E, Beuerlein K, Schmidt H, et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation. 2006;113:286-295. doi: 10.1161/CIRCULATIONAHA.105.581405
24. Schermuly RT, Stasch JP, Pullamsetti SS, Middendorff R, Müller D, Schlüter KD, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J. 2008;32:881-891. doi: 10.1183/09031936.00114407
25. Vermeersch P, Buys E, Pokreisz P, Marsboom G, Ichinose F, Sips P, et al. Soluble guanylate cyclase-alpha1 deficiency selectively inhibits the pulmonary vasodilator response to nitric oxide and increases the pulmonary vascular remodeling response to chronic hypoxia. Circulation. 2007;116:936-943. doi: 10.1161/CIRCULATIONAHA.106.677245
26. Lang M, Kojonazarov B, Tian X, Kalymbetov A, Weissmann N, Grimminger F, et al. The soluble guanylate cyclase stimulator riociguat ameliorates pulmonary hypertension induced by hypoxia and SU5416 in rats. PLoS One. 2012;7:e43433. doi: 10.1371/journal.pone.0043433
27. Russwurm M, Wittau N, Koesling D. Guanylyl cyclase/PSD-95 interaction: targeting of the nitric oxide-sensitive alpha2beta1 guanylyl cyclase to synaptic membranes. J Biol Chem. 2001;276:44647-44652. doi: 10.1074/jbc. M105587200
28. Venema RC, Venema VJ, Ju H, Harris MB, Snead C, Jilling T, et al. Novel complexes of guanylate cyclase with heat shock protein 90 and nitric oxide synthase. Am J Physiol Heart Circ Physiol. 2003;285:H669-H678. doi: 10.1152/ajpheart.01025.2002
29. Hanafy KA, Martin E, Murad F. CCTeta, a novel soluble guanylyl cyclaseinteracting protein. J Biol Chem. 2004;279:46946-46953. doi: 10.1074/ jbc.M404134200
30. Erdmann J, Stark K, Esslinger UB, Rumpf PM, Koesling D, de Wit C, et al.; CARDIOGRAM. Dysfunctional nitric oxide signalling increases risk of myocardial infarction. Nature. 2013;504:432-436. doi: 10.1038/nature12722
31. International Consortium for Blood Pressure Genome-Wide Association Studies. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature. 2011;478:103-109
32. Buys ES, Raher MJ, Kirby A, Shahid M, Mohd S, Baron DM, et al. Genetic modifiers of hypertension in soluble guanylate cyclase 1-deficient mice. J Clin Invest. 2012;122:2316-2325. doi: 10.1172/JCI60119
33. Dweik RA, Laskowski D, Abu-Soud HM, Kaneko F, Hutte R, Stuehr DJ, et al. Nitric oxide synthesis in the lung. Regulation by oxygen through a kinetic mechanism. J Clin Invest. 1998;101:660-666. doi: 10.1172/JCI1378
34. Beall CM, Laskowski D, Strohl KP, Soria R, Villena M, Vargas E, et al. Pulmonary nitric oxide in mountain dwellers. Nature. 2001;414:411-412. doi: 10.1038/35106641
35. Erzurum SC, Ghosh S, Janocha AJ, Xu W, Bauer S, Bryan NS, et al. Higher blood flow and circulating NO products offset high-altitude hypoxia among Tibetans. Proc Natl Acad Sci U S A. 2007;104:17593-17598. doi: 10.1073/ pnas.0707462104
36. Hoit BD, Dalton ND, Erzurum SC, Laskowski D, Strohl KP, Beall CM. Nitric oxide and cardiopulmonary hemodynamics in Tibetan highlanders. J Appl Physiol (1985). 2005;99:1796-1801. doi: 10.1152/ japplphysiol.00205.2005
37. Beall CM, Cavalleri GL, Deng L, Elston RC, Gao Y, Knight J, et al. Natural selection on EPAS1 (HIF2alpha) associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci U S A. 2010;107:11459-11464. doi: 10.1073/pnas.1002443107
38. Yi X, Liang Y, Huerta-Sanchez E, Jin X, Cuo ZX, Pool JE, et al. Sequencing of 50 human exomes reveals adaptation to high altitude. Science. 2010;329:75-78. doi: 10.1126/science.1190371
39. Peng Y, Yang Z, Zhang H, Cui C, Qi X, Luo X, et al. Genetic variations in Tibetan populations and high-altitude adaptation at the Himalayas. Mol Biol Evol. 2011;28:1075-1081. doi: 10.1093/molbev/msq290
40. Wang B, Zhang YB, Zhang F, Lin H, Wang X, Wan N, et al. On the origin of Tibetans and their genetic basis in adapting high-altitude environments. PLoS One. 2011;6:e17002. doi: 10.1371/journal. pone.0017002
41. Xiang K, Ouzhuluobu, Peng Y, Yang Z, Zhang X, Cui C, et al. Identification of a Tibetan-specific mutation in the hypoxic gene EGLN1 and its contribution to high-altitude adaptation. Mol Biol Evol. 2013;30:1889-1898. doi: 10.1093/molbev/mst090
42. Ji LD, Qiu YQ, Xu J, Irwin DM, Tam SC, Tang NL, et al. Genetic adaptation of the hypoxia-inducible factor pathway to oxygen pressure among Eurasian human populations. Mol Biol Evol. 2012;29:3359-3370. doi: 10.1093/molbev/mss144.